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Enterococci are opportunistic bacteria that cause severe infections in animals
and humans, capable to acquire, express, and transfer antimicrobial resistance.
Susceptibility to 21 antimicrobial agents was tested by the disk diffusion method in
222 Enterococcus spp. strains isolated from the fecal samples of 287 healthy domestic
dogs. Vancomycin and ampicillin minimum inhibitory concentrations (MICs) and
high-level aminoglycoside resistance (HLAR) tests were also performed. Isolates
showed resistance mainly to streptomycin (88.7%), neomycin (80.6%), and tetracy-
cline (69.4%). Forty-two (18.9%) isolates showed an HLAR to streptomycin and 15
(6.7%) to gentamicin. Vancomycin and ampicillin MIC values showed 1 and 18
resistant strains, respectively. One hundred and thirty-six (61.2%) strains were
classiﬁed as multidrug resistant and six (2.7%) strains as possibly extensively
drug-resistant bacteria. Enterococcus faecium and Enterococcus faecalis were the
most prevalent antimicrobial resistant species. Companion animals, which often live in
close contact with their owners and share the same environment, represent a serious
source of enterococci resistant to several antibiotics; for this reason, they may be a
hazard for public health by providing a conduit for the entrance of resistance genes into
the community.
Keywords: Enterococcus spp., dogs, feces, antimicrobial resistance, high-level
aminoglycoside resistance (HLAR)
Introduction
Enterococcus species are Gram-positive bacteria belonging to the gastroin-
testinal microbiota of humans and animals, mammals and birds, and are widely
distributed in the environment such as terrestrial and water habitats [1]. Some
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Enterococcus species are used as probiotics to treat diarrhea and improve host
immunity [2].
Enterococci are opportunistic pathogens for humans and animals. Entero-
coccus faecalis and Enterococcus faecium have become particularly important
etiological agents of human nosocomial infections, including urinary tract infec-
tions, endocarditis, bacteremia, neonatal infections, central nervous system,
abdominal, pelvic, and endodontic infections [1, 3].
Enterococci are also involved as etiological agents of infections in veterinary
medicine such as mastitis in cattle, enteritis in swine and cattle, as well as
endocarditis, septicemia, spondylitis, and amyloid arthropathy in poultry [4, 5].
Companion animals are often reservoirs of zoonotic pathogens for their
owners. In dogs, enterococci may not only be involved in the urinary tract
infections, but also in diarrhea, endocarditis, post-surgical, and periodontal
infections [6, 7]. However, domestic dogs, even though without clinical forms,
may excrete enterococci in their feces contaminating the environment shared by
humans.
Enterococci are of particular concern for their intrinsic antibiotic resistance,
particularly to cephalosporins and aminoglycosides, or acquired resistance to many
other antimicrobials [8]. Moreover, these bacteria in the gastrointestinal habitat are
in a suitable position to acquire antimicrobial resistance genes from other com-
mensals, which may further transfer to other more pathogenic bacteria [9].
The aim of the present study was to investigate the antimicrobial resistance
proﬁles of Enterococcus spp. strains isolated from feces of healthy domestic dogs,
with particular attention to vancomycin, ampicillin, and high-level aminoglyco-
side resistance (HLAR).
Materials and Methods
Sampling
Fecal swabs were collected from 287 clinically healthy dogs, which were
regularly kept indoor, strictly in contact with their owners. Samples were collected
during routine visits to local veterinarians and kept at 4 °C until bacteriological
examinations.
Bacterial isolation
Within 24 h from collection, swabs were cultured directly on Kanamycin
Aesculin Azide Agar (KAAA, Oxoid Ltd., Basingstoke, UK) and incubated at
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42± 1 °C for 18–24 h. From plates with growth of colonies typical for entero-
cocci, at least one colony was subcultured on KAAA.
Isolates were stored at −80 °C in Brain Hearth Infusion Broth (Oxoid Ltd.)
for further investigations.
Antimicrobial susceptibility testing
Disk diffusion method. Isolates were tested by the standard disk diffusion method of
Kirby–Bauer [10] on Mueller–Hinton Agar (Oxoid Ltd.) incubated at 35± 1 °C
for 18–24 h. The following antimicrobials (Oxoid Ltd.) were tested: amoxicillin–
clavulanic acid (30 μg), ampicillin (10 μg), cefalotin (30 μg), chloramphenicol
(30 μg), ciproﬂoxacin (5 μg), clindamycin (2 μg), enroﬂoxacin (5 μg), erythro-
mycin (10 μg), gentamicin (10 μg), linezolid (30 μg), neomycin (10 μg), nitrofur-
antoin (300 μg), oxacillin (1 μg), quinupristin–dalfopristin (15 μg), rifampicin
(30 μg), streptomycin (10 μg), teicoplanin (30 μg), tetracycline (30 μg), tigecycline
(15 μg), trimethoprim (5 μg), and vancomycin (30 μg). Results were interpreted
following EUCAST breakpoint tables and, where not possible, according to
National Committee for Clinical Laboratory Standards (NCCLS) [11, 12]. Refer-
ence strains E. faecalis ATCC 29212 and E. faecium ATCC 19434 were used
as controls.
Minimum inhibitory concentration (MIC) determination. MIC for vancomycin
and ampicillin were performed on microplates [13]. Concentrations from 0.5 to
256 μg/ml were used to test vancomycin MIC and concentrations from 8 to
256 μg/ml were used for ampicillin MIC. Microplates were incubated at 37± 1 °C
in a humid chamber. Breakpoint values are 32 μg/ml for vancomycin and 64 μg/ml
for ampicillin.
HLAR. As indicated by CLSI Performance Standards for antimicrobial suscep-
tibility tests, isolates that showed resistance to gentamicin and/or streptomycin by
disk diffusion method, were tested for resistance to high concentration of
gentamicin (500 μg/ml) and streptomycin (1,000 μg/ml) [13].
Classiﬁcation of acquired resistance
To classify isolated strains for expression of acquired resistance, a stan-
dardized international terminology proposed by Magiorakos et al. [14] has been
used in this study. For enterococci, aminoglycosides, carbapenems, ﬂuoro-
quinolones, glycopeptides, glycylcyclines, lipopeptides, oxazolidinones, penicil-
lins, streptogramins, and tetracycline categories should be tested. Criteria for
deﬁning acquired resistance are: multidrug-resistant (MDR) strain when it is
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non-susceptible to ≥1 agent in ≥3 antimicrobial categories, extensively drug-
resistant (XDR) strain when it is non-susceptible to ≥1 agent in all but ≤2
categories, and pandrug-resistant (PDR) strain when it is non-susceptible to all
antimicrobial agents listed.
Since no all proposed antibiotics have been tested in our study, only MDR or
possibly XDR strains could be detected.
Species identiﬁcation
Enterococcus spp. isolates classiﬁed as MDR or possibly XDR were exam-
ined for species identiﬁcation with API 20 STREP (Bio Mérieux Italia, Bagno a
Ripoli, FI, Italy). Apiweb V 1.1.0 software was used as interpretative criteria.
Results
Bacterial isolation
Two hundred and twenty-two Enterococcus spp. isolates were obtained
from the 287 examined fecal samples, with a 77.3% prevalence of shedding dogs.
Antimicrobial susceptibility testing
Disk diffusion method. All 222 strains were tested for antimicrobial susceptibility
by disk diffusion method and the results were reported in Table I.
The isolates were more frequently non-susceptible to aminoglycosides
category (92.3% of isolates were non-susceptible to neomycin and 94.1% to
streptomycin), trimethoprim (97.3%), tetracycline (88.7%), ﬂuoroquinolones
(80.2% to enroﬂoxacin and 77.9% to ciproﬂoxacin), clindamycin (71.2%), and
oxacillin (71.6%).
A moderate percentage of isolates were non-susceptible to erythromycin
(64%), gentamicin (56.8%), cefalotin (49.5%), quinupristin–dalfopristin (45.5%),
linezolid (43.2%), and tigecycline (40.5%).
A limited number of isolates were non-susceptible to glycopeptides (van-
comycin 9.5% and teicoplanin 7.7%), ampicillin (12.2%) and association of
amoxicillin–clavulanic acid (6.8%).
A total of 165 resistance patterns were identiﬁed and all Enterococcus spp.
isolates were resistant to at least two different categories of antibiotics, with
182 (81.9%) isolates being resistant to ﬁve or more antibiotics.
304 BERTELLONI ET AL.
Acta Microbiologica et Immunologica Hungarica 64, 2017
T
ab
le
I.
A
nt
im
ic
ro
bi
al
re
si
st
an
ce
ex
pr
es
si
on
of
E
nt
er
oc
oc
cu
s
sp
p.
is
ol
at
es
by
di
sk
di
ff
us
io
n
m
et
ho
d
an
d
th
e
re
su
lts
A
nt
ib
io
tic
s
S
us
ce
pt
ib
le
(N
o.
of
is
ol
at
es
)
%
In
te
rm
ed
ia
te
(N
o.
of
is
ol
at
es
)
%
R
es
is
ta
nt
(N
o.
of
is
ol
at
es
)
%
N
on
-s
us
ce
pt
ib
le
:
in
te
rm
ed
ia
te
+
re
si
st
an
t
(N
o.
of
is
ol
at
es
)
%
A
m
in
og
ly
co
si
de
N
eo
m
yc
in
(N
)
17
7.
7
26
11
.7
17
9
80
.6
20
5
92
.3
G
en
ta
m
ic
in
(C
N
)
96
43
.2
40
18
.0
86
38
.7
12
6
56
.8
S
tr
ep
to
m
yc
in
(S
)
13
5.
9
12
5.
4
19
7
88
.7
20
9
94
.1
C
ep
ha
lo
sp
or
in
s
C
ef
al
ot
in
(K
F
)
11
2
50
.5
46
20
.7
64
28
.8
11
0
49
.5
F
lu
or
oq
ui
no
lo
ne
s
C
ip
ro
ﬂ
ox
ac
in
(C
IP
)
49
22
.1
96
43
.2
77
34
.7
17
3
77
.9
E
nr
oﬂ
ox
ac
in
(E
N
R
)
44
19
.8
68
30
.6
11
0
49
.5
17
8
80
.2
G
ly
co
pe
pt
id
e
T
ei
co
pl
an
in
(T
E
C
)
20
5
92
.3
10
4.
5
7
3.
2
17
7.
7
V
an
co
m
yc
in
(V
A
)
20
1
90
.5
13
5.
9
8
3.
6
21
9.
5
P
en
ic
ill
in
s
A
m
ox
ic
ill
in
+
cl
av
ul
an
ic
ac
id
(A
M
C
)
20
7
93
.2
10
4.
5
5
2.
3
15
6.
8
A
m
pi
ci
lli
n
(A
M
P
)
19
5
87
.8
0
0
27
12
.2
27
12
.2
O
xa
ci
lli
n
(O
X
)
63
28
.4
8
3.
6
15
1
68
.0
15
9
71
.6
T
et
ra
cy
cl
in
e
T
et
ra
cy
cl
in
e
(T
E
)
25
11
.3
43
19
.4
15
4
69
.4
19
7
88
.7
T
ig
ec
yc
lin
e
(T
G
C
)
13
2
59
.5
47
21
.2
43
19
.4
90
40
.5
M
ac
ro
lid
es
E
ry
th
ro
m
yc
in
(E
)
80
36
.0
66
29
.7
76
34
.2
14
2
64
.0
L
in
co
sa
m
id
es
Q
ui
nu
pr
is
tin
+
da
lf
op
ri
st
in
(Q
D
)
12
1
54
.5
46
20
.7
55
24
.8
10
1
45
.5
S
tr
ep
to
gr
am
in
s
C
lin
da
m
yc
in
(D
A
)
64
28
.8
34
15
.3
12
4
55
.9
15
8
71
.2
O
th
er
s
R
if
am
pi
ci
n
(R
D
)
15
1
68
.0
23
10
.4
48
21
.6
71
32
.0
C
hl
or
am
ph
en
ic
ol
(C
)
15
5
69
.8
29
13
.1
38
17
.1
67
30
.2
L
in
ez
ol
id
(L
Z
D
)
12
6
56
.8
31
14
.0
65
29
.3
96
43
.2
N
itr
of
ur
an
to
in
(F
)
14
8
66
.7
19
8.
6
55
24
.8
74
33
.3
T
ri
m
et
ho
pr
im
(W
)
6
2.
7
61
27
.5
15
5
69
.8
21
6
97
.3
ANTIBIOTIC-RESISTANT ENTEROCOCCI IN DOGS 305
Acta Microbiologica et Immunologica Hungarica 64, 2017
MIC determination. All isolates characterized by a non-susceptibility to vanco-
mycin and/or ampicillin with Kirby–Bauer test were tested for determination of
MIC of these antibiotics.
Vancomycin MIC showed the following results: ≥256 μg/ml (1 isolate),
4 μg/ml (2 isolates), 2 μg/ml (9 isolates), 1 μg/ml (8 isolates), and 0.5 μg/ml
(1 isolate).
Considering 32 μg/ml as breakpoint, one isolate was conﬁrmed resistant to
the antibiotic.
Ampicillin MIC showed the following results: >256 μg/ml (5 isolates),
256 μg/ml (2 isolates), 128 μg/ml (7 isolates), 64 μg/ml (4 isolates), 32 μg/ml
(5 isolates), 16 μg/ml (2 isolates), and <8 μg/ml (3 isolates). Considering 64 μg/ml
as breakpoint, 18 isolates resulted resistant to ampicillin.
HLAR. One hundred and twenty-six (56.8%) isolates that were non-
susceptible to gentamicin and 209 (94.1%) to streptomycin with Kirby–Bauer
test, were tested for the HLAR. Fifteen (6.7%) tested isolates showed a
high level resistance to gentamicin, whereas 42 (18.9%) isolates showed a
high level resistance to streptomycin. Six (2.7%) of these isolates had
HLAR to both antibiotics. Table II shows the resistance patterns of the HLAR
strains.
Classiﬁcation of acquired resistance and species identiﬁcation
Following MDR, XDR, and PDR classiﬁcation, 136 (61.2%) strains were
classiﬁed as MDR and 6 (2.7%) strains as possibly XDR bacteria. MDR isolates
were distributed among the species E. faecium (63 strains), E. faecalis (56
strains), E. durans (13 strains), E. casseliﬂavus (3 strains), and E. avium
(1 strain). XDR isolates belonged to the species E. faecium (4 strains) and
E. faecalis (2 strains). Table III reports the resistance patterns of the six XDR
isolates.
Table II. Resistance patterns of strains classiﬁed as possibly XDR
Resistance patterns Strain Species
C; LZD; F; N; KF; CIP; ENR; TEC; E; QD; DA; AMP; TE; TIG E239 E. faecium
RD; C; LZD; N; S (HLAR); KF; CIP; ENR; E; QD; DA; AMP; TE; TIG E233 E. faecalis
RD; C; LZD; N; S; KF; CIP; ENR; TEC; E; QD; DA; TE; TIG E218 E. faecium
RD; C; LZD; F; N; KF; CIP; ENR; TEC; E; QD; AMP; TE; TIG E160 E. faecium
RD; C; LZD; F; N; KF; CIP; ENR; TEC; E; QD; DA; AMP; TE; TIG E177 E. faecium
RD; C; LZD; F; N; CN (HLAR); S (HLAR); KF; CIP; ENR; TE; E; QD;
DA; TE; TIG
E234 E. faecalis
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Table III. Resistance patterns of Enterococcus strains resulted high-level aminoglycoside resistance
(HLAR) to gentamicin and/or streptomycin
Resistance patterns Species
N; ENR; E; QD; DA; TE; CN (HLAR); S (HLAR) E. faecium MDR
RD; C; LZD; F; N; KF; E; QD; DA; AMC; TE; CN (HLAR); S (HLAR) E. faecium MDR
RD; N; KF; ENR; E; QD; DA; TE; CN (HLAR); S (HLAR) E. faecalis MDR
C; N; CIP; ENR; E; DA; TIG; S (HLAR) NT
N; CIP; TE; S (HLAR) E. faecalis MDR
LZD; N; CIP; ENR; E;QD; TE; S (HLAR) E. durans MDR
N;CIP; ENR; E; DA; TE; S (HLAR) E. faecium MDR
RD; N; KF; E; QD; DA; TE; S (HLAR) E. faecium MDR
N; CIP; ENR; TE; S (HLAR) E. faecium MDR
N; CIP; ENR; DA; TE; S (HLAR) E. faecium (2 strains) MDR
C; F; N; KF; CIP; ENR; QD; DA; AMC; AMP; TE; TIG; S (HLAR) E. faecalis MDR
C; F; KF; E; QD; DA; TE; S (HLAR) E. faecium MDR
RD; C; LZD; N; KF; CIP, ENR; E; QD; DA; TE; TIG; S (HLAR);
CN (HLAR)
E. faecium (2 strains) MDR
E. faecalis (1 strain) MDR
E. durans (1 strain) MDR
RD; C; LZD; F; N; CIP, ENR; E; QD, DA, TE; TIG; CN (HLAR) E. faecalis MDR
N; CIP; ENR; QD; TE; TIG; CN (HLAR) E. faecalis MDR
RD; C; LZD; N; KF; CIP, ENR; TEC; E; QD; D; TE; TIG;
CN (HLAR)
E. faecium MDR
RD; C; LZD; F; N; CIP; ENR; E; QD; DA; TE; TIG; CN (HLAR) E. faecium MDR
C; LZD; F; N; KF; CIP; ENR; E; QD; DA; TE; TIG; CN (HLAR) E. faecium MDR
N, KF, CIP; E; QD; DA; TE; TIG; S (HLAR) E. faecalis MDR
N; CIP; ENR; E; QD; DA; TE; S (HLAR) E. faecium MDR
RD; C; LZD; N; KF; CIP; ENR; E; QD; DA; TE; S (HLAR) E. faecium MDR
C; LZD; N; CIP; ENR; TEC; E; DA; TE; S (HLAR) E. faecium MDR
N; ENR; E, DA; TE; S (HLAR) E. faecium MDR
RD; LZD; N; KF; CIP, ENR; E; QD, DA; TE; TIG; S (HLAR) E. faecium (1 strain) MDR
E. casseliﬂavus (1 strain)
MDR
RD; C; LZD; N; KF; CIP; ENR; TEC; E; QD; DA; TE; TIG;
S (HLAR)
E. faecium XDR
RD; C; LZD; F; N; KF; CIP; ENR, E; QD; DA; TE; TIG;
S (HLAR)
E. faecalis MDR
RD; C; LZD, F; N; KF; CIP; ENR; E; QD; DA; AMC; TE; TIG;
S (HLAR)
E. durans MDR
RD; C; LZD; N; KF; CIP; ENR; E; QD; DA; AMP; TE; TIG;
S (HLAR)
E. faecalis XDR
RD; C; LZD; F; N; KF; CIP; ENR; TE; E; QD; DA; TE; TIG; CN
(HLAR); S (HLAR)
E. faecalis XDR
RD; N, KF; CIP; ENR, E; DA; TE; TIG; S (HLAR) E. durans MDR
RD; C; LZD; N; CN (HLAR); KF; CIP, ENR, E;QD; DA; AMP, TE;
TIG
E. faecium MDR
N; DA; TE; S (HLAR) NT
RD; N; CN; KF; CIP; ENR; E; QD; DA; TE; S (HLAR) E. faecium MDR
C; LZD, F; N; KF; CIP; ENR; E; DA; AMC; AMP; TE; TIG;
S (HLAR)
E. faecalis MDR
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Discussion
During the present investigation, Enterococcus spp. strains were isolated
from almost all tested dogs. E. faecium and E. faecalis were most frequently
isolated, in agreement to the results obtained by other studies [15–17].
High degrees of antimicrobial activity were observed among penicillins. The
association of amoxicillin and clavulanic acid resulted active against 93.2% of
strains and ampicillin against 87.8% of strains. Other studies found higher values
of resistance in enterococci from pets [17].
Most of the isolates showed resistance to aminoglycosides, particularly
streptomycin (94.1% non-susceptible) and neomycin (92.3% non-susceptible).
These results could be related to the intrinsic resistance of enterococci to clinically
achievable concentrations of aminoglycosides due to the inability to enter the
cell and for enzyme-mediated resistance or sterically hindered ribosome target
site [18].
A low percentage of isolates showed resistance to vancomycin with the
Kirby–Bauer test, and MIC determination conﬁrmed this resistance only in one
case. This result, in agreement to other studies [16], suggests that dogs are not an
important reservoir of vancomycin-resistant enterococci (VRE), even though VRE
have been isolated from canine feces hypothesizing dogs as a source of infection
for their owners [15].
Considering the tetracyclines class, 88.7% and 40.5% of isolates resulted
non-susceptible to tetracycline and tigecycline, respectively. Resistance to tetra-
cycline is common among enterococci, because of their large employment in
human and veterinary medicine [19].
Tigecycline is a bacteriostatic antibiotic active against a broad range of
bacteria, with only few naturally resistant exceptions [20]. Instead, our result
suggests that resistance to tigecycline is not so uncommon and could be a new
threat in the therapy of infections.
Table III. (cont.)
Resistance patterns Species
C; LZD; N; E; DA; TE; CN; S (HLAR) E. faecalis MDR
RD; C; F; N; ENR; E; QD, DA; TE; TIG; S (HLAR) E. faecalis MDR
N; E; QD; DA; TE; S (HLAR) E. faecium MDR
N; E; DA; TE; S (HLAR) NT
LZD; F; N; CIP; ENR; TE; QD; DA; S (HLAR) E. faecium MDR
C; LZD; N; KF; E; DA, TE; TIG; CN (HLAR); S (HLAR) E. durans – MDR
Note: NT = not typed since MDR or XDR is not detected.
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Diffuse resistance to ﬂuoroquinolones was detected: this result seems to be
related to their large employment in human and veterinary medicine due to their
effectiveness against both Gram-positive and Gram-negative bacteria [21].
Forty-ﬁve percent of isolates were non-susceptible to quinupristin–
dalfopristin. Thirty-ﬁve isolates showed concomitant resistance to erythromycin,
clindamycin, and quinupristin–dalfopristin, suggesting an acquired macrolide–
lincosamide–streptogramin (MLSB) resistance. MLSB resistance is well charac-
terized in enterococci and three mechanisms of acquired resistance have been
described: methylation of 23S rRNA, active efﬂux, or inactivating enzymes [22].
The percentage of linezolid-resistant isolates found in the present study
shows the increasing resistance to this antibiotic, that has been often used against
complicated glycopeptide-resistant enterococci infections, mainly human endo-
carditis [18].
HLAR has been tested on the isolates with a non-susceptible phenotype in
the Kirby–Bauer test for streptomycin and gentamicin. Forty-two (18.9%) isolates
showed an HLAR to streptomycin and 15 (6.7%) to gentamicin, and among them
six (2.7%) to both.
Recommended therapy for serious infections like endocarditis, meningitis,
or possibly other serious infections in immunodeﬁciency human patients includes
a cell-wall-active agent such as penicillin or vancomycin, combined with an
aminoglycoside like gentamicin or streptomycin. This combination is synergistic
in action. However, when an Enterococcus strain is resistant to the cell-wall-active
agent or has HLAR, there is no synergism and the combination therapy is likely to
be unsuccessful [23].
Although the clinical use of streptomycin for enterococci has long
been restricted due to intrinsic low level resistance, the present study revealed
a relevant number of strains with HLAR to this antibiotic. The present investiga-
tion found a higher percentage of strains with HLAR to streptomycin, whereas
previous studies indicated HLAR to gentamicin to be more common in all species
of enterococci [24].
Conclusion
Infections caused by enterococci are not frequent in companion animals.
However, antibiotic therapy against other infections in these animals allows the
selection of antimicrobial resistant Enterococcus strains as well as other bacteria.
The presence of antimicrobial-resistant Enterococcus strains in the intestinal
microﬂora of animals represents a severe risk of genetic linkage of resistance
genes with other bacteria [25]. Moreover, companion animals, that often live in
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close contact with their owners, may serve as reservoirs of antimicrobial resistance
genes that can be transferred from pets to humans and within the environment.
In the past, the main threat related to enterococci antibiotic resistance was
the circulation of VRE among humans and animals [26]. Currently, on the basis of
more recent studies and our results, VRE seem to be not frequent in pet population,
but other concerns have been added: the increasing spread of enterococci resistant
to several other antimicrobials.
In light of these considerations, it is important to monitor the extent of
antimicrobial resistant enterococci in companion animals, in order to determine the
role of pets as reservoirs of bacterial strains with old and new antimicrobial
resistance patterns.
Conﬂict of Interest
The authors declare that they have no conﬂict of interest.
References
1. Byappanahalli, M. N., Nevers, M. B., Korajkic, A., Staley, Z. R., Harwood, V. J.:
Enterococci in the environment. Microbiol Mol Bio Rev 4, 685–706 (2012).
2. Franz, C. M., Huch, M., Abriouel, H., Holzapfel, W., Galvez, A.: Enterococci as probiotics
and their implications in food safety. Int J Food Microbiol 151, 125–140 (2011).
3. Herczegh, A., Gyurkovics, M., Ghidan, A., Megyesi, M., Lohinai, Z.: Effect of dentin
powder on the antimicrobial properties of hyperpure chlorine-dioxide and its comparison to
conventional endodontic disinfecting agents. Acta Microbiol Immunol Hung 61, 209–220
(2014).
4. Robbins, K. M., Suyemoto, M. M., Lyman, R. L., Martin, M. P., Barnes, H. J., Borst, L. B.:
An outbreak and source investigation of enterococcal spondylitis in broiler caused by
Enterococcus cecorum. Avian Dis 56, 768–773 (2012).
5. Šeputienė, V., Bogdaitė, A., Ružauskas, M., Sužiedėlienė, E.: Antibiotic resistance genes
and virulence factors in Enterococcus faecium and Enterococcus faecalis from diseased
farm animals: Pigs, cattle and poultry. Pol J Vet Sci 3, 431–438 (2012).
6. Abbot, Y., Kirby, B. M., Karczmarczk, M., Markey, B. K., Leonard, F. C., Fitzgerald, S.:
High-level gentamicin-resistant and vancomycin-resistant Enterococcus faecium isolated
from a wound in a dog. J Small Anim Pract 50, 194–197 (2009).
7. Semedo-Lemsaddek, T., Tavares, M., São Braz, B., Tavares, L., Oliveira, M.: Enterococcal
infective endocarditis following periodontal disease in dogs. PLoS One 11, e0146860 (2016).
8. Tendolkar, P. M., Baghdayan, A. S., Shankar, N.: Pathogenic enterococci: New develop-
ments in the 21st century. Cell Mol Life Sci 60, 2622–2636 (2003).
9. Hegstad, K., Mikalsenm, T., Coque, T. M., Werner, G., Sundsfjord, A.: Mobile genetics
elements and their contribution to the emergence of antimicrobial resistant Enterococcus
faecalis and Enterococcus faecium. Clin Microbiol Infect 16, 541–554 (2010).
310 BERTELLONI ET AL.
Acta Microbiologica et Immunologica Hungarica 64, 2017
10. Bauer, A., Kirby, W. M. N., Sherris, J. C., Turk, M.: Antibiotic susceptibility testing by a
standardized single disc method. Am J Pathol 45, 493–496 (1966).
11. Clinical and Laboratory Standards Institute (CLSI): Performance standards for antimicro-
bial susceptibility testing, seventeenth informational supplement. Clinical and Laboratory
Standards Institute document M100-S17, Clinical and Laboratory Standards Institute,
Wayne, PA, USA, 2007.
12. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint
tables for interpretation of MICs and zone diameters. Version 3.1, 2013. Retrieved from
http://www.eucast.org
13. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial
susceptibility tests for bacteria that grow aerobically; approved standard, Seventh edition.
Clinical and Laboratory Standards Institute document M7-A7. Clinical and Laboratory
Standards Institute, Wayne, PA, USA, 2006.
14. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G.,
Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice,
L. B., Stelling, J., Struelens, M. J., Vatopoulos, A., Weber, J. T., Monnet, D. L.: Multidrug-
resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert
proposal for interim standard deﬁnitions for acquired resistance. Clin Microbiol Infect 18,
268–281 (2012).
15. Devriese, L. A., Cruz Colque, J. I., De Herdt, P., Haesebrouck, F.: Identiﬁcation and
composition of the tonsillar and anal enterococcal and streptococcal ﬂora of dogs and cats.
J Appl Bacteriol 73, 421–425 (1992).
16. Ossiprandi, M. C., Bottarelli, E., Cattabiani, F., Bianchi, E.: Susceptibility to vancomycin
and other antibiotics of 165 Enterococcus strains isolated from dogs in Italy. Comp
Immunol Microbiol Infect Dis 31, 1–9 (2008).
17. Iseppi, R., Messi, P., Anacarso, I., Bondi, M., Sabia, C., Condò, C., de Niederhausern, S.:
Antimicrobial resistance and virulence traits in Enterococcus strains isolated from dogs and
cats. New Microbiol 38, 369–378 (2015).
18. Hollenbeck, B. L., Rice, L. B.: Intrinsic and acquired resistance mechanisms in Entero-
coccus. Virulence 5, 421–433 (2012).
19. Guardabassi, L., Schwarz, S., Lloyd, D. H.: Pet animals as reservoirs of antimicrobial-
resistant bacteria. J Antimicrob Chemother 54, 321–332 (2004).
20. Sun, Y., Cai, Y., Liu, X., Bai, N., Liang, B., Wang, R.: The emergence of clinical resistance
to tigecycline. Int J Antimicrob Agents 41, 110–116 (2013).
21. Redgrave, L. S., Sutton, S. B., Webber, M. A., Piddock, L. J. V.: Fluoroquinolone
resistance: Mechanism, impact on bacteria, and role in evolutionary success. Trends
Microbiol 22, 438–445 (2014).
22. Jaglic, Z., Vlkova, H., Bardon, J., Michu, E., Cervinkova, D., Babak, V.: Distribution,
characterization and genetic bases of erythromycin resistance in staphylococci and entero-
cocci originating from livestock. Zoonoses Public Health 59, 202–211 (2012).
23. Adhikari, L.: High-level aminoglycoside resistance and reduced susceptibility to vanco-
mycin in nosocomial enterococci. J Glob Infect Dis 2, 231–235 (2010).
24. Padmasini, E., Padmaraj, R., Srivani Ramesh, S.: High level aminoglycoside resistance and
distribution of aminoglycoside resistant genes among clinical isolates of Enterococcus
species in Chennai, India. Sci World J 2014, 329157 (2014).
ANTIBIOTIC-RESISTANT ENTEROCOCCI IN DOGS 311
Acta Microbiologica et Immunologica Hungarica 64, 2017
25. Jackson, C. R., Fedorka-Cray, P. J., Davis, J. A., Barrett, J. B., Brousse, J. H., Gustafson, J.,
Kucher, M.: Mechanisms of antimicrobial resistance and genetic relatedness among
enterococci isolated from dogs and cats in the United States. J Appl Microbiol 108,
2171–2179 (2010).
26. Jovanovic´, M., Miloševic´, B., Tošic´, T., Stevanovic´, G., Mioljevic´, V., Indic´, N., Velebit,
B., Zervos, M.: Molecular typing, pathogenicity factor genes and antimicrobial suscepti-
bility of vancomycin resistant enterococci in Belgrade, Serbia. Acta Microbiol Immunol
Hung 62, 147–160 (2015).
312 BERTELLONI ET AL.
Acta Microbiologica et Immunologica Hungarica 64, 2017
